CHMP Clears First mAb Biosimilar Under New EU Path

The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization for Pebrilzo, Biocon Biologics’ biosimilar of the breast-cancer antibody pertuzumab — without requiring the dedicated comparative efficacy trial that biosimilar sponsors have built their development programs around for more than a decade. CHMP adopted the positive opinion on 17 September 2026, making Pebrilzo the first monoclonal antibody biosimilar cleared under the agency’s new “tailored clinical approach,” a pathway that lets extensive analytical characterization and comparative pharmacokinetic data stand in for a Phase 3 efficacy study.

What 'tailored clinical approach' means in practice

Biosimilar sponsors have historically had to run a dedicated, randomized comparative efficacy trial against the reference product — typically the single most expensive and time-consuming piece of a biosimilar development program, and one increasingly criticized as adding little scientific value once a biosimilar has been shown, through analytics, to be highly similar to its reference. EMA's tailored clinical approach, set out in a reflection paper drafted in April 2025 and finalized earlier in 2026, formalizes an alternative: where robust analytical and functional characterization plus comparative pharmacokinetic data already demonstrate high similarity, EMA says it no longer expects a separate comparative efficacy study. Pebrilzo's application relied on exactly that combination — structural and functional analytical characterization plus comparative clinical PK data against Perjeta — with no dedicated efficacy trial in the file.

Why a monoclonal antibody is the harder test

EMA's own stated rollout sequence made monoclonal antibodies a later, harder case for the tailored approach: simpler, well-characterized biologics such as filgrastim (G-CSF), insulin, and somatropin were expected to qualify first, given decades of manufacturing and clinical experience and comparatively simple molecular structures. Monoclonal antibodies are larger, more structurally complex molecules, with more potential sources of variability in glycosylation and other post-translational modifications that could plausibly affect clinical performance in ways analytics alone might miss. A positive CHMP opinion for a pertuzumab biosimilar on this basis is a live signal to the wider biosimilar industry — including sponsors developing biosimilars of other complex antibodies — that advanced analytics and PK comparability can, in practice, carry a mAb biosimilar through CHMP review without a dedicated efficacy trial.

What Pebrilzo is proposed to treat

• Neoadjuvant treatment, in combination with trastuzumab and chemotherapy, of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence.
• Adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.
• Metastatic or locally recurrent unresectable breast cancer, in combination with trastuzumab and docetaxel, in patients who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease.
• Shreehas Tambe, CEO and Managing Director of Biocon, said in the company's statement that the opinion "marks an important step toward expanding access to biologic therapies for patients with HER2-positive breast cancer in Europe."

What happens next

A CHMP positive opinion is a recommendation, not an authorization. The European Commission now conducts its own review of the opinion before issuing a legally binding decision on EU-wide marketing authorization; Pebrilzo cannot be marketed anywhere in the EU until that decision is issued. Once authorized, an EMA-published European Public Assessment Report will set out CHMP's full scientific assessment, including the analytical and pharmacokinetic data underlying the tailored-approach decision — a document biosimilar sponsors elsewhere are likely to read closely as a template for how much analytical and PK evidence CHMP is willing to accept in place of an efficacy trial for a complex antibody.

Frequently asked questions

What did CHMP recommend?

A positive opinion for Pebrilzo, Biocon Biologics' biosimilar of pertuzumab (reference product: Roche's Perjeta), a 420 mg concentrate for solution for infusion, for HER2-positive breast cancer. CHMP adopted the opinion on 17 September 2026 at its 14-17 September plenary.

Why is this a 'first'?

Pebrilzo is the first monoclonal antibody biosimilar to receive a positive CHMP opinion under EMA's tailored clinical approach, in which extensive analytical and structural characterization plus comparative pharmacokinetic data substitute for a dedicated randomized comparative efficacy trial. It is not the first biosimilar overall under the approach — EMA has said it expects the tailored approach to apply first to simpler, well-understood biologics such as G-CSF, insulin, and somatropin before extending to monoclonal antibodies.

What is Pebrilzo approved to treat?

As proposed, three settings in HER2-positive breast cancer: neoadjuvant treatment (with trastuzumab and chemotherapy) of locally advanced, inflammatory, or early-stage disease at high risk of recurrence; adjuvant treatment of early breast cancer at high risk of recurrence; and, with trastuzumab and docetaxel, metastatic or locally recurrent unresectable disease in patients who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease.

What happens next?

The European Commission conducts its own review of the CHMP opinion before issuing a final decision on EU-wide marketing authorization. Pebrilzo is not authorized for use anywhere in the EU until that decision is issued; Commission decisions on CHMP positive opinions typically follow within roughly two months, though EMA does not commit to a fixed timeline for any individual product.